CO2020001346A2 - Pirrolopirimidina y derivados de pirrolopirimidina - Google Patents

Pirrolopirimidina y derivados de pirrolopirimidina

Info

Publication number
CO2020001346A2
CO2020001346A2 CONC2020/0001346A CO2020001346A CO2020001346A2 CO 2020001346 A2 CO2020001346 A2 CO 2020001346A2 CO 2020001346 A CO2020001346 A CO 2020001346A CO 2020001346 A2 CO2020001346 A2 CO 2020001346A2
Authority
CO
Colombia
Prior art keywords
diseases
pyrrolopyrimidine
compounds
prophylaxis
complications
Prior art date
Application number
CONC2020/0001346A
Other languages
English (en)
Inventor
David Amantini
Milan Mesic
Gordon Saxty
Tanja Poljak
Ines Vujasinovic
Dinko Ziher
David Witty
Karl Richard Gibson
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CO2020001346A2 publication Critical patent/CO2020001346A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención está relacionada con compuestos de pirrolopirimidina de acuerdo con la Fórmula I y su uso en la profilaxis y/o el tratamiento del dolor, afecciones inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, enfermedades neurológicas, complicaciones de la diabetes tipo I, el cáncer y/o enfermedades fibróticas. En un aspecto particular, los compuestos de la presente son inhibidores de ASK (quinasa reguladora de la señal de apoptosis, por sus siglas en inglés). La presente invención también proporciona métodos para la producción de un compuesto de la invención, composiciones farmacéuticas que comprenden un compuesto de la invención, el uso de los compuestos en la profilaxis y/o el tratamiento del dolor, de afecciones inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, enfermedades neurológicas, complicaciones de la diabetes tipo I, el cáncer y/o enfermedades fibróticas.
CONC2020/0001346A 2017-07-12 2020-02-06 Pirrolopirimidina y derivados de pirrolopirimidina CO2020001346A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1711234.3A GB201711234D0 (en) 2017-07-12 2017-07-12 Pyrrolopyrimidine and pyrrolopyridine derivatives
PCT/GB2018/051983 WO2019012284A1 (en) 2017-07-12 2018-07-12 PYRROLOPYRIMIDINE AND ASK1 INHIBITING PYRROLOPYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CO2020001346A2 true CO2020001346A2 (es) 2020-05-29

Family

ID=59676761

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001346A CO2020001346A2 (es) 2017-07-12 2020-02-06 Pirrolopirimidina y derivados de pirrolopirimidina

Country Status (18)

Country Link
US (2) US11136325B2 (es)
EP (1) EP3652173A1 (es)
JP (1) JP7198263B2 (es)
KR (1) KR20200028436A (es)
CN (1) CN111094283A (es)
AR (1) AR112333A1 (es)
AU (1) AU2018300218B2 (es)
BR (1) BR112020000578A2 (es)
CA (1) CA3069358A1 (es)
CO (1) CO2020001346A2 (es)
GB (1) GB201711234D0 (es)
IL (1) IL271910B2 (es)
MX (1) MX2020000005A (es)
PH (1) PH12019502823A1 (es)
SG (1) SG11202000168UA (es)
TW (1) TWI794253B (es)
UY (1) UY37809A (es)
WO (1) WO2019012284A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CN111303155A (zh) * 2020-03-13 2020-06-19 深圳大学 靶向pak1抑制剂及其在抗肿瘤治疗药物中的应用
CN111704617B (zh) * 2020-06-15 2022-08-23 嘉兴特科罗生物科技有限公司 一种小分子化合物
KR102635126B1 (ko) * 2021-05-27 2024-02-13 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도
TW202310836A (zh) * 2021-07-28 2023-03-16 美商埃皮里姆生物股份有限公司 吡咯并[2,3-b]吡啶PGDH抑制劑及製備與使用方法
WO2023014049A1 (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731520A1 (en) 1999-12-02 2006-12-13 OSI Pharmaceuticals, Inc. Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
TW200306191A (en) * 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
WO2004048565A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited アポトーシス関連蛋白質およびその用途
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2651417B1 (en) * 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives

Also Published As

Publication number Publication date
WO2019012284A1 (en) 2019-01-17
CA3069358A1 (en) 2019-01-17
TWI794253B (zh) 2023-03-01
RU2020106289A (ru) 2021-08-12
MX2020000005A (es) 2020-08-06
BR112020000578A2 (pt) 2020-07-14
AU2018300218A1 (en) 2020-02-27
US20220169653A1 (en) 2022-06-02
CN111094283A (zh) 2020-05-01
UY37809A (es) 2019-02-28
RU2020106289A3 (es) 2021-11-10
EP3652173A1 (en) 2020-05-20
JP2020530833A (ja) 2020-10-29
GB201711234D0 (en) 2017-08-23
AR112333A1 (es) 2019-10-16
AU2018300218B2 (en) 2021-12-16
PH12019502823A1 (en) 2020-10-26
SG11202000168UA (en) 2020-02-27
IL271910B2 (en) 2023-07-01
IL271910A (en) 2020-02-27
US11136325B2 (en) 2021-10-05
TW201908312A (zh) 2019-03-01
US20200165259A1 (en) 2020-05-28
IL271910B1 (en) 2023-03-01
KR20200028436A (ko) 2020-03-16
JP7198263B2 (ja) 2022-12-28

Similar Documents

Publication Publication Date Title
CO2020001346A2 (es) Pirrolopirimidina y derivados de pirrolopirimidina
ECSP20060827A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CO2021003036A2 (es) Compuestos de anillo fusionado
CO2021008224A2 (es) Inhibidores de kif18a
CO2022010241A2 (es) Inhibidores de sos1
CO2017011484A2 (es) Inhibidores de bromodominio
CO2018006475A2 (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
ECSP17023551A (es) Inhibidores de histona desmetilasa
CO2020012169A2 (es) Compuestos de aminopirazina diol como inhibidores de pi3k-y
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
UY37225A (es) Inhibidores del potenciador del homólogo zeste 2 campo de la invención
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2020003862A (es) Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.